Day: December 23, 2023

Nano Dimension Announces Preliminary All Cash Proposal to Acquire Stratasys for $16.50 per share

Nano Dimension Announces Preliminary All Cash Proposal to Acquire Stratasys for $16.50 per share

Waltham, Mass., Dec. 23, 2023 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension”, or “Nano” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, today announced that it has submitted a preliminary all cash proposal to the Board of Directors of Stratasys Ltd. (Nasdaq: SSYS) (“Stratasys”) to purchase all the outstanding shares of Stratasys that it does not currently own for $16.50 per share in cash, with an ability to increase its price subject to due diligence. This proposal represents a 40% premium from the volume-weighted average Stratasys share price since September 28, 2023, the day that Stratasys announced that its Board of Directors initiated a process to explore strategic alternatives...

Continue reading

U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility The CRL is related to deficiencies identified at a third-party manufacturing facility following an inspection but are not specific to dasiglucagon. The CRL did not state any concerns about the clinical data package or safety of dasiglucagon. Copenhagen, Denmark, December 23, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for...

Continue reading

31/2023・Trifork Holding AG – Weekly report on share buyback

31/2023・Trifork Holding AG – Weekly report on share buyback

Company announcement no. 31 / 2023Schindellegi, Switzerland – 23 December 2023 Trifork Holding AG – Weekly report on share buyback On 2 November 2023, Trifork initiated a share buyback program in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buyback program runs from 2 November 2023 up to and including no later than 31 March 2024. For details, please see announcement no. 17 of 31 October 2023. Under the share buyback program, Trifork will purchase shares for up to a total of DKK 15 million (approximately EUR 2 million). Prior to the launch of the share buyback, Trifork held 232,497 treasury shares, corresponding to 1.2% of the share capital. Under the program, the following transactions have been...

Continue reading

TRESU Investment Holding A/S – Settlement of interest payment by issuance of interest bonds

TRESU Investment Holding A/S – Settlement of interest payment by issuance of interest bonds

TRESU INVESTMENT HOLDING A/S ANNOUNCEMENT NO. 14.2023 23.12.2023 TRESU Investment Holding A/S – Settlement of interest payment by issuance of interest bonds Capitalised terms used but not defined are used with the meanings given to them in the Terms and Conditions (as defined below). TRESU Investment Holding A/S gives notice to the holders of its Senior Secured Floating Rate Bonds 2017/2027 with ISIN no. DK0030404967 (the “Bonds”) issued pursuant to the terms and conditions originally dated 22 September 2017 as last amended and restated on 22 December 2023 (the “Terms and Conditions“) that the Interest Payment Test has not been met in respect of the Interest Payment Date on 29 December 2023 and that it will settle the payment of Interest that should have been made on 29 December 2023 by issuance of Interest Bonds in accordance...

Continue reading

Mirasol Resources Announces Annual Option Grants

Mirasol Resources Announces Annual Option Grants

VANCOUVER, British Columbia, Dec. 22, 2023 (GLOBE NEWSWIRE) — Mirasol Resources Ltd. (TSX-V: MRZ) (OTCPK: MRZLF) (the “Company” or “Mirasol”) announced today that the Board of Directors has approved the grant of 1,713,750 incentive stock options (“Options”) under the Company’s long-term incentive plan. The grants were made to employees, officers, directors, and consultants of the Company. The Options entitle the holders to purchase the equivalent number of common shares of the Company at a price of $0.72 per common share for a period of five years from the date of grant. The options granted to employees will vest as follows: 25% on the date of grant, followed by an additional 25% each six months thereafter. All grants of Options are subject to the Company’s Stock Option Plan which was approved by shareholders at Mirasol’s annual...

Continue reading

AYURCANN ANNOUNCES AGSM RESULTS

AYURCANN ANNOUNCES AGSM RESULTS

Toronto, Ontario, Dec. 22, 2023 (GLOBE NEWSWIRE) — Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian cannabis extraction company, specializing in the processing and co-manufacturing of pharma grade cannabis and hemp to produce various derivative cannabis 2.0 and 3.0 products in the medical and recreational market, is pleased to provide the following corporate updates. Annual General and Special Meeting The Company is pleased to announce that its voting results from its annual general and special meeting of shareholders of the Company (the “Shareholders”) held on December 20, 2023 (the “Meeting”). Shareholders voted in favour of each resolution put forward at the Meeting at a passing rate of over 96%, including approval of each of the Future Share Issuance Resolution...

Continue reading

Harfang Announces Closing of Private Placement

Harfang Announces Closing of Private Placement

MONTREAL, Dec. 22, 2023 (GLOBE NEWSWIRE) — (TSX-V: HAR) (“Harfang” or the “Company”) is pleased to announce that it has completed a non-brokered private placement for gross proceeds of $940,500 (the “Private Placement”). Pursuant to the Private Placement, Harfang issued an aggregate of (a) 2,733,333 flow-through common shares as a part of a charity arrangement (the “Charity FT Shares”) at $0.30 per Charity FT Share and (b) 573,811 flow-through common shares (the “FT Shares”) at $0.21 per FT Share. “We are excited to welcome a new institutional shareholder to Harfang and would like to thank the continued support of our existing shareholders participating in this placement,” said Rick Breger, President. “With this additional liquidity, we further reinforce our optionality and financial flexibility. We, at Harfang, are all looking...

Continue reading

POWR Lithium Discovers up to 1,735 ppm Lithium in Maiden Drilling Campaign

POWR Lithium Discovers up to 1,735 ppm Lithium in Maiden Drilling Campaign

Hole No. Halo-001-23 intersects broad Li-bearing claystone interval with 125.4 feet (38.2 m) of 938 ppm Lithium Figure 1 POWR Land Package Figure 1. Map of the POWR land package showing drill hole and neighboring land positions. VANCOUVER, British Columbia, Dec. 22, 2023 (GLOBE NEWSWIRE) — POWR Lithium Corp. (CSE: POWR) (FRA: 6JX / WKN: A3D6BS) (OTCQB: PWRLF) (“POWR” or the “Company”), a mineral exploration and development company focused on American lithium deposits to support domestic demand, is pleased to provide the initial results from a four-hole, 2,899 feet (883.9-metre) HQ core program. The Halo project is located less than 3 kilometres northwest of Tonopah, NV and surrounded by several lithium-exploration companies with published resources or, at least, discoveries (see Figure 1). Highlights: Results from the first...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.